Core Viewpoint - Rongchang Biopharmaceutical (688331.SH) has received approval from the National Medical Products Administration for its clinical trial of the dual-antibody ADC drug RC288, aimed at treating locally advanced unresectable or metastatic malignant solid tumors in I/IIa phases [1]. Group 1 - The company announced the receipt of the clinical trial approval notice on April 1 [1]. - The drug RC288 is a self-developed dual-antibody ADC targeting specific cancer types [1]. - The approval marks a significant step in the company's research and development efforts in oncology [1].